JP2021528480A5 - - Google Patents
Info
- Publication number
- JP2021528480A5 JP2021528480A5 JP2021502738A JP2021502738A JP2021528480A5 JP 2021528480 A5 JP2021528480 A5 JP 2021528480A5 JP 2021502738 A JP2021502738 A JP 2021502738A JP 2021502738 A JP2021502738 A JP 2021502738A JP 2021528480 A5 JP2021528480 A5 JP 2021528480A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862651133P | 2018-03-31 | 2018-03-31 | |
| US62/651,133 | 2018-03-31 | ||
| PCT/US2019/025234 WO2019191776A1 (en) | 2018-03-31 | 2019-04-01 | Selective anti-cancer agent effective for prevention and treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528480A JP2021528480A (ja) | 2021-10-21 |
| JP2021528480A5 true JP2021528480A5 (enExample) | 2022-04-06 |
| JP7491514B2 JP7491514B2 (ja) | 2024-05-28 |
Family
ID=66175524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502738A Active JP7491514B2 (ja) | 2018-03-31 | 2019-04-01 | 予防及び治療に有効な選択的抗がん剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11083714B2 (enExample) |
| EP (1) | EP3773582B1 (enExample) |
| JP (1) | JP7491514B2 (enExample) |
| CN (1) | CN112601527B (enExample) |
| WO (1) | WO2019191776A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114224832A (zh) * | 2022-02-11 | 2022-03-25 | 明度智云(浙江)科技有限公司 | 一种恩杂鲁胺注射剂及其制备方法和应用 |
| EP4784106A1 (en) * | 2023-09-27 | 2026-08-05 | Jina Pharmaceuticals, Inc. | Compositions containing cabazitaxel and lipids for oral administration |
| CN121466043A (zh) * | 2026-01-09 | 2026-02-06 | 哈尔滨医科大学 | 香叶醇在制备胃癌化疗增敏剂中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415831A (en) | 1965-07-16 | 1968-12-10 | Smith Kline French Lab | 2-isoquinolinyl(and carbolinyl) alkyloctahydroindolo [2,3-a]-quinolizines |
| US3468890A (en) | 1966-06-09 | 1969-09-23 | Sterling Drug Inc | Pyrazino(1',2':1,2)pyrido(3,4-b)indoles |
| US3455936A (en) | 1967-04-18 | 1969-07-15 | Smithkline Corp | Substituted indolo(2,3-a)quinolizinium salts |
| US3943148A (en) | 1970-05-19 | 1976-03-09 | American Home Products Corporation | Indole fused heterocyclic diuretic compounds |
| US3814773A (en) | 1970-05-19 | 1974-06-04 | American Home Prod | Indole fused heterocyclic anti-inflammatory compounds |
| HU169916B (enExample) | 1974-09-27 | 1977-02-28 | ||
| FR2419725A1 (fr) | 1978-03-13 | 1979-10-12 | Beljanski Mirko | Serpentine, alstonine et sempervirine, medicaments inhibant specifiquement les cellules cancereuses et tumorales |
| FR2450607A2 (fr) | 1978-03-13 | 1980-10-03 | Beljanski Mirko | Composition pharmaceutique contenant comme principe actif la flavopereine |
| HU183234B (en) | 1980-10-17 | 1984-04-28 | Richter Gedeon Vegyeszet | Process for the enantioselective synthesis of optically active cys-14-oxo-e-homo-eburnan |
| DE3172570D1 (en) | 1981-03-11 | 1985-11-14 | Mirko Beljanski | Serpentine, alstonine and sempervirine drugs for the specific inhibition of tumurous and cancerous cells |
| FR2639830B1 (fr) | 1988-12-02 | 1991-03-22 | Beljanski Mirko | Composition antivirale et ses applications |
| FR2694693B1 (fr) | 1992-07-28 | 1994-10-28 | Abrax Bio Labs Sa | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. |
| FR2751969B1 (fr) | 1996-08-01 | 1998-12-04 | Centre Nat Rech Scient | Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant |
| WO2002094270A2 (en) | 2001-05-18 | 2002-11-28 | Chemokine Therapeutics Corporation | Mip-1 alpha receptor ligands - drugs for t-cell mediated and autoimmune diseases |
| WO2003082866A1 (en) | 2002-04-03 | 2003-10-09 | Orion Corporation | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
| JP4468638B2 (ja) | 2003-01-31 | 2010-05-26 | アリジェン製薬株式会社 | インドール骨格を有するアルカロイドを含有するアスコフラノンの抗原虫作用増強剤およびこれらを含む抗原虫作用を有する薬剤組成物 |
| AU2005219508B2 (en) | 2004-02-18 | 2012-02-16 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor |
| US20090215853A1 (en) | 2004-05-19 | 2009-08-27 | Natural Source International | Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer |
| DE602004021439D1 (de) | 2004-06-11 | 2009-07-16 | Dabur Pharma Ltd | Flavopereirinderivate zur krebstherapie |
| JP2012097060A (ja) | 2010-11-01 | 2012-05-24 | Tottori Univ | 新規ジヒドロキシベンゼン誘導体およびそれらを有効成分とする抗原虫剤 |
-
2019
- 2019-04-01 EP EP19717684.5A patent/EP3773582B1/en active Active
- 2019-04-01 JP JP2021502738A patent/JP7491514B2/ja active Active
- 2019-04-01 US US17/042,786 patent/US11083714B2/en active Active
- 2019-04-01 WO PCT/US2019/025234 patent/WO2019191776A1/en not_active Ceased
- 2019-04-01 CN CN201980036058.2A patent/CN112601527B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy | |
| CN114641293A (zh) | 一种fgfr抑制剂的用途 | |
| JP2021098728A5 (enExample) | ||
| JP2021512121A5 (enExample) | ||
| JP2019509253A5 (enExample) | ||
| JP2009515901A5 (enExample) | ||
| JP2011515481A (ja) | 癌の処置のための方法および組成物 | |
| JP2023548055A5 (enExample) | ||
| JP2017527582A5 (enExample) | ||
| JP2009506054A5 (enExample) | ||
| Sayed et al. | Antitumor and radiosensitizing effects of zinc oxide-caffeic acid nanoparticles against solid ehrlich carcinoma in female mice | |
| JP2022500479A5 (enExample) | ||
| JP2023102786A5 (enExample) | ||
| Kuang et al. | Celecoxib in oncology: targeting the COX-2/PGE2 axis to reprogram the tumor immune microenvironment and enhance multimodal therapy | |
| JP2021505669A5 (enExample) | ||
| JP2021511344A5 (enExample) | ||
| Li et al. | Sesquiterpene lactones and cancer: new insight into antitumor and anti-inflammatory effects of parthenolide-derived Dimethylaminomicheliolide and Micheliolide | |
| JP2023550740A5 (enExample) | ||
| CN104434939B (zh) | 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用 | |
| Sun et al. | The role of NLRP3 inflammasome in digestive system malignancy | |
| JP2022500431A5 (enExample) | ||
| JP2021517886A5 (enExample) | ||
| Sonkar et al. | Antiproliferative effect of indeno [1, 2-d] thiazolo [3, 2-a] pyrimidine analogues on IL-6 mediated STAT3 and role of the apoptotic pathway in albino Wistar rats of ethyl carbamate-induced lung carcinoma: In-silico, In-vitro, and In-vivo study | |
| JP2024520307A5 (enExample) | ||
| CN104146999B (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 |